Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Century Therapeutics' Depreciation & Amortization (CF) fell 509.55% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 493.46%. This contributed to the annual value of $13.3 million for FY2024, which is 199.33% up from last year.
  • Latest data reveals that Century Therapeutics reported Depreciation & Amortization (CF) of $3.1 million as of Q3 2025, which was down 509.55% from $3.2 million recorded in Q2 2025.
  • Century Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $3.6 million during Q4 2023, with a 5-year trough of $1.2 million in Q1 2022.
  • For the 4-year period, Century Therapeutics' Depreciation & Amortization (CF) averaged around $3.0 million, with its median value being $3.2 million (2025).
  • Per our database at Business Quant, Century Therapeutics' Depreciation & Amortization (CF) skyrocketed by 15068.97% in 2023 and then crashed by 753.9% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then rose by 25.16% to $3.6 million in 2023, then fell by 6.59% to $3.3 million in 2024, then dropped by 5.7% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.2 million for Q2 2025, and $3.2 million during Q1 2025.